--- source_url: "https://www.kopilo.ai/?utm_source=openai" title: "7Scholar | Source-grounded document workflow for medical writing" mirrored_at: 2026-08-12T01:02:26.825Z host: www.kopilo.ai cited_in_42a: true mirror_canonical: "https://index.42a.ai/www.kopilo.ai/index__q__utm_source_openai" --- > **Original source:** https://www.kopilo.ai/?utm_source=openai Turn client inputs and literature into a traceable draft where every claim is linked to its source. Watch Demo One workspace. All deliverables. For diverse and source-heavy medical communications. ### Regulatory writings Clinical Study ReportCTD Module 2 DossierClinical Protocol & SAPInvestigator BrochureDevice Clinical (CER)IVD Performance (PER)Risk Management PlanDSUR & PSUR Reports ### Publications Primary trial manuscriptNarrative review articleRWE manuscriptSecondary/Ad-hoc manuscriptCongress abstract & posterPlain language summary ### Medical affairs Core scientific narrativeAd board briefing bookAd board summary reportMSL slide decksStandard response doc (SRD)Objection handlersMedical information letters Draft · Verify · Defend Every claim stays connected to the supporting evidence or literature. Draft Combination therapy reduced mortality (HR, 0.68; 95% CI, 0.57–0.80) versus ADT alone. Overall survival was the primary endpoint. Consistent with earlier docetaxel evidence.1 TFL.xlsxVerified Table 14.2 · row 22 HR 0.68 (0.57–0.80) Overall survival — hazard ratio 0.68 (95% CI, 0.57–0.80); P<0.001. Source link Protocol.docxVerified §8.1 Endpoints The primary endpoint was overall survival, defined as the time from randomization to death from any cause. Source link Smith MR, et al. N Engl J Med. 2022Verified Reference 1 Darolutamide plus androgen-deprivation therapy and docetaxel significantly increased overall survival versus placebo. Publication citation Security & Privacy Your data remains isolated to your workspace and never used to train models. ### Your work never trains a model. Not ours, and not the model providers'. Your sources, project instructions, and drafts stay yours alone, so you can use 7Scholar with confidential material without giving it away. No model trainingEU data in the EEA ### GDPR Compliant For all EU users, data is stored and processed within the European Economic Area under the GDPR. ### Legally binding commitments All safety, privacy, and security promises are documented in legally binding agreements that you can present to clients to prove reliability. ### Private to your workspace Authentication, authorization, and workspace-level controls keep project material separated and available only to your authorized users. ### Deletion you can rely on After account deletion, most data is purged within 30 days and remaining logs and backups within a maximum of 90 days. How it works? Review, edit, reorder, then approve or reject the proposed structure before drafting. * * * Command AI to write and edit in a Word-like document alongside you. * * * Review 7Scholar's suggested reporting guideline, or upload your own. * * * Review supporting literature 7Scholar finds and screens, then add approved papers to your project. * * * Import your EndNote library for drafting, then export to Word with native EndNote citations. Who's in control? 7Scholar accelerates the work without taking over the judgment. Frequently Asked Questions Evidence stays inspectable The writer approves the work Your data is not used for training 7Scholar keeps the project connected from evidence intake through delivery: bring together papers and client materials, organize and inspect sources, shape the document, develop a cited draft, review claims against their evidence, and move the finished work to Word with its references. Claims stay connected to their supporting evidence. You can inspect the cited paper passage or the relevant location in project material such as a protocol, SAP, or TFL, then decide whether the wording is accurate, appropriately qualified, and ready to keep. 7Scholar grounds drafting in the sources you select and makes the evidence trail visible, so the writer can challenge, edit, and approve every final claim. Scientific judgment and final sign-off remain with the team. Your project data stays private and is not used for model training. Because client and sponsor policies differ, you should still follow the data-handling rules for each engagement. We can review 7Scholar's security and data practices with you or your team before a live project. You can work from the mixed source packs medical writers actually receive, including journal articles, Word files, PDFs, TFLs and other spreadsheets, protocols, SAPs, client briefs, templates, reference libraries, and pasted context. Yes. You choose the evidence and review the document structure before drafting. You can apply relevant reporting guidance, add a client or journal template, edit the text directly, and accept or reject AI-proposed changes. 7Scholar assists the workflow; it does not lock the writer out of it. 7Scholar is designed to work with the tools medical writers already use. Bring references into the project, manage citations alongside the draft, and move the deliverable back to Microsoft Word with its references. EndNote-compatible workflows are part of the source-to-delivery experience. The current focus is source-heavy publications and medical communications work: journal manuscripts, literature and evidence reviews, scientific content, and related deliverables. Regulatory workflows are a deliberate next area, so we will be direct about fit before you start a project.